6MAR

HIV-1 Envelope Glycoprotein Clone BG505 delCT N332T in complex with broadly neutralizing antibody Fab PGT151

6MAR の概要

• エントリーDOI: 10.2210/pdb6mar/pdb
• EMDBエントリー: 9062
• 分子名称: Immunoglobulin G PGT151 Fab, Heavy chain, alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-3)-alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (13 entities in total)
• 機能のキーワード: fusion protein-fab complex, membrane protein
• 由来する生物種: Homo sapiens; 詳細
• タンパク質・核酸の鎖数: 10
• 化学式量合計: 366670.05

構造登録者

Berndsen, Z.T.,Ward, A.B. (登録日: 2018-08-28, 公開日: 2018-09-26, 最終更新日: 2024-11-20)

主引用文献

Cao, L.,Pauthner, M.,Andrabi, R.,Rantalainen, K.,Berndsen, Z.,Diedrich, J.K.,Menis, S.,Sok, D.,Bastidas, R.,Park, S.R.,Delahunty, C.M.,He, L.,Guenaga, J.,Wyatt, R.T.,Schief, W.R.,Ward, A.B.,Yates, J.R.,Burton, D.R.,Paulson, J.C.
Differential processing of HIV envelope glycans on the virus and soluble recombinant trimer.
Nat Commun, 9:3693-3693, 2018

PubMed Abstract: As the sole target of broadly neutralizing antibodies (bnAbs) to HIV, the envelope glycoprotein (Env) trimer is the focus of vaccination strategies designed to elicit protective bnAbs in humans. Because HIV Env is densely glycosylated with 75-90 N-glycans per trimer, most bnAbs use or accommodate them in their binding epitope, making the glycosylation of recombinant Env a key aspect of HIV vaccine design. Upon analysis of three HIV strains, we here find that site-specific glycosylation of Env from infectious virus closely matches Envs from corresponding recombinant membrane-bound trimers. However, viral Envs differ significantly from recombinant soluble, cleaved (SOSIP) Env trimers, strongly impacting antigenicity. These results provide a benchmark for virus Env glycosylation needed for the design of soluble Env trimers as part of an overall HIV vaccine strategy.

PubMed: 30209313
DOI: 10.1038/s41467-018-06121-4

実験手法

ELECTRON MICROSCOPY (4.5 Å)